PMID- 34370483
OWN - NLM
STAT- MEDLINE
DCOM- 20220127
LR  - 20220127
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 18
IP  - 9
DP  - 2021 Sep 6
TI  - ERK-Peptide-Inhibitor-Modified Ferritin Enhanced the Therapeutic Effects of 
      Paclitaxel in Cancer Cells and Spheroids.
PG  - 3365-3377
LID - 10.1021/acs.molpharmaceut.1c00303 [doi]
AB  - Rational design of a drug delivery system with enhanced therapeutic potency is 
      critical for efficient tumor chemotherapy. Many protein-based drug delivery 
      platforms have been designed to deliver drugs to target sites and improve the 
      therapeutic efficacy. In this study, paclitaxel (PTX) molecules were encapsulated 
      within an apoferritin nanocage-based drug delivery system with the modification 
      of an extracellular-signal-regulated kinase (ERK) peptide inhibitor at the 
      C-terminus of ferritin (HERK). Apoferritin is an endogenous nano-sized spherical 
      protein which has the ability to specially bind to a majority of tumor cells via 
      interacting with transferrin receptor 1. The ERK peptide inhibitor is a peptide 
      which can disrupt the interaction of MEK with ERK in the mitogen-activated 
      protein kinase/ERK pathway. By combining the targeted delivery effect of ferritin 
      and the inhibitory effect of the ERK peptide inhibitor, the newly fabricated 
      ferritin carrier nanoparticle HERK could still be taken up by tumor cells, and it 
      displayed higher cell cytotoxicity than the parent ferritin. After loading with 
      PTX, HERK-PTX displayed a favorable anticancer effect in human breast cancer 
      cells MDA-MB-231 and lung carcinoma cells A549. The remarkable inhibitory effect 
      on MDA-MB-231 tumor spheroids was also identified. These results indicated that 
      the constructed HERK nanocarrier is a promising multi-functional drug delivery 
      vehicle to enhance the therapeutic effect of drugs in cancer therapy.
FAU - Dong, Yixin
AU  - Dong Y
AUID- ORCID: 0000-0002-5898-9785
AD  - College of Chemical Engineering, Jiangsu Co-Innovation Center of Efficient 
      Processing and Utilization of Forest Resources, Jiangsu Provincial Key Laboratory 
      for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Laboratory 
      of Biomass-Based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 
      210037, P. R. China.
FAU - Ma, Yuanmeng
AU  - Ma Y
AD  - College of Chemical Engineering, Jiangsu Co-Innovation Center of Efficient 
      Processing and Utilization of Forest Resources, Jiangsu Provincial Key Laboratory 
      for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Laboratory 
      of Biomass-Based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 
      210037, P. R. China.
FAU - Li, Xun
AU  - Li X
AUID- ORCID: 0000-0002-1267-9263
AD  - College of Chemical Engineering, Jiangsu Co-Innovation Center of Efficient 
      Processing and Utilization of Forest Resources, Jiangsu Provincial Key Laboratory 
      for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Laboratory 
      of Biomass-Based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 
      210037, P. R. China.
FAU - Wang, Fei
AU  - Wang F
AUID- ORCID: 0000-0001-6428-5111
AD  - College of Chemical Engineering, Jiangsu Co-Innovation Center of Efficient 
      Processing and Utilization of Forest Resources, Jiangsu Provincial Key Laboratory 
      for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Laboratory 
      of Biomass-Based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 
      210037, P. R. China.
FAU - Zhang, Yu
AU  - Zhang Y
AUID- ORCID: 0000-0002-2614-5975
AD  - College of Chemical Engineering, Jiangsu Co-Innovation Center of Efficient 
      Processing and Utilization of Forest Resources, Jiangsu Provincial Key Laboratory 
      for the Chemistry and Utilization of Agro-Forest Biomass, Jiangsu Key Laboratory 
      of Biomass-Based Green Fuels and Chemicals, Nanjing Forestry University, Nanjing 
      210037, P. R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210809
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Nanoparticle Drug Delivery System)
RN  - 0 (Peptides)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 9007-73-2 (Ferritins)
RN  - 9013-31-4 (Apoferritins)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/pharmacokinetics
MH  - Apoferritins/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Drug Liberation
MH  - Drug Screening Assays, Antitumor
MH  - Drug Synergism
MH  - Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors
MH  - Ferritins/chemistry
MH  - Humans
MH  - Nanoparticle Drug Delivery System/chemistry/*pharmacology
MH  - Paclitaxel/*administration & dosage/pharmacokinetics
MH  - Peptides/chemistry/pharmacology
MH  - Protein Kinase Inhibitors/chemistry/pharmacology
MH  - Spheroids, Cellular
OTO - NOTNLM
OT  - ERK peptide inhibitor
OT  - drug delivery
OT  - encapsulation
OT  - ferritin
OT  - paclitaxel
EDAT- 2021/08/10 06:00
MHDA- 2022/01/28 06:00
CRDT- 2021/08/09 17:13
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2022/01/28 06:00 [medline]
PHST- 2021/08/09 17:13 [entrez]
AID - 10.1021/acs.molpharmaceut.1c00303 [doi]
PST - ppublish
SO  - Mol Pharm. 2021 Sep 6;18(9):3365-3377. doi: 10.1021/acs.molpharmaceut.1c00303. 
      Epub 2021 Aug 9.